Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1986-7-18
pubmed:abstractText
Serum, urine, tissue, and body fluids were collected from 40 adult patients who were receiving imipenem/cilastatin treatment for serious infections. Thirty-two patients were given 1 g every 6 h (4 g/day), and eight received 500 mg (2 g/day). Mean peak concentrations in serum were 34.9 +/- 4.0 micrograms/ml for the 1-g dose and 26.6 +/- 2.5 micrograms/ml for the 500-mg dose. Trough levels were 3.1 and 1.0 micrograms/ml, respectively. No evidence of drug accumulation was found after comparing peaks measured early in the treatment with those measured late. Peak levels were only marginally increased when infusions were given over 30 versus 60 min. The mean serum half-life was 82.0 +/- 25.3 min, with a range of 50 to 138 min. The apparent volume of distribution was 0.35 +/- 0.13 liter/kg, and the mean total body clearance was 0.183 +/- 0.067 liter/kg per h. Creatinine clearance correlated directly with the plasma elimination rate and inversely with the serum half-life. Moreover, total body clearance fell as the age of the patient rose. The mean urinary recovery was 39.1 +/- 12.8% (range, 15.0 to 59.2%) and did not correlate with creatinine clearance until it was below 15 ml/min. Of 20 specimens of various gastrointestinal secretions, 13 had imipenem concentrations that were low, but above the MIC for most resident flora. Pus, sputum, and bone all had concentrations of the drug sufficient to inhibit the infecting organisms, and these levels reflected generally excellent clinical responses.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-3860187, http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-6389126, http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-6573157, http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-6581755, http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-6583194, http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-6594237, http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-6595963, http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-6619054, http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-6931548, http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-6931549, http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-6934708, http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-6979306, http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-7249588, http://linkedlifedata.com/resource/pubmed/commentcorrection/3459389-950590
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
188-92
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't